Figure 3.
Figure 3. In vivo treatment with anti-c-kit antibody (ACK2) during T spiralis infection successfully depleted GHP and nGHP c-kit+ cells in the bone marrow. (A) Naive mice treated with ACK2 for 8 days. No population changes were observed despite detection of antibody binding. (B) Noticeable population changes in GHP (boxed area) began to occur on day 8 after infection in the ACK2-treated group. (C) Ten days after infection the GHP was severely depleted in the ACK2-treated group. (D) Ex vivo staining with an alternative anti-c-kit antibody (2B8) confirmed the absence of c-kit+ cells in the ACK2-treated group. (E) Cell number recovery on day 10 is due primarily to an increase in B cells. (A-C) Shaded areas indicate IgG-treated group; solid lines, ACK2-treated group. (D-E) Shaded area indicates isotype control; solid line, ACK2-treated group; dashed line, IgG-treated group.

In vivo treatment with anti-c-kit antibody (ACK2) during T spiralis infection successfully depleted GHP and nGHP c-kit+ cells in the bone marrow. (A) Naive mice treated with ACK2 for 8 days. No population changes were observed despite detection of antibody binding. (B) Noticeable population changes in GHP (boxed area) began to occur on day 8 after infection in the ACK2-treated group. (C) Ten days after infection the GHP was severely depleted in the ACK2-treated group. (D) Ex vivo staining with an alternative anti-c-kit antibody (2B8) confirmed the absence of c-kit+ cells in the ACK2-treated group. (E) Cell number recovery on day 10 is due primarily to an increase in B cells. (A-C) Shaded areas indicate IgG-treated group; solid lines, ACK2-treated group. (D-E) Shaded area indicates isotype control; solid line, ACK2-treated group; dashed line, IgG-treated group.

Close Modal

or Create an Account

Close Modal
Close Modal